2,3-Dihydroxypropyl docosanoate;2-[4-(2-methylpropyl)phenyl]propanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2,3-Dihydroxypropyl docosanoate;2-[4-(2-methylpropyl)phenyl]propanoic acid
• 英文别名: 2,3-dihydroxypropyl docosanoate;2-[4-(2-methylpropyl)phenyl]propanoic acid
• 化学式: C38H68O6
• 分子量: 620.9
• InChiKey: PVEHGMAGVMIPMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.78
• 重原子数：
  44
• 可旋转键数：
  28
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES FOR USE IN ORAL DOSAGE FORMS
  申请人：McNeil-PPC, Inc.

  公开号：EP2897584A1

  公开（公告）日：2015-07-29
• SUSTAINED RELEASE ORAL DOSAGE FORMS COMPRISING LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES
  申请人：McNeil-PPC, Inc.

  公开号：EP2897646A1

  公开（公告）日：2015-07-29
• SUSPENSION PHARMACEUTICAL FORMULATIONS COMPRISING LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES
  申请人：McNeil-PPC, Inc.

  公开号：EP2897647A1

  公开（公告）日：2015-07-29
• Sustained Release Oral Dosage Forms Comprising Low Melting Propionic Acid Derivative Particles
  申请人：McNeil-PPC, Inc.

  公开号：US20140079796A1

  公开（公告）日：2014-03-20

  Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.
• Suspension Pharmaceutical Formulations Comprising Low Melting Propionic Acid Derivative Particles
  申请人：McNeil-PPC, Inc.

  公开号：US20140080912A1

  公开（公告）日：2014-03-20

  Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.